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Summary
The present study was undertaken to define the cellular mechanisms involved in the rejection
of major histocompatibility complex (MHC) class I disparate skin grafts by mice depleted of
CD8+ T cells in vivo. Mice were effectively depleted ofCD8+ T cells by adult thymectomy
followed by in vivo administration of anti-CD8 monoclonal antibody (mAb) and then engrafted
with allogeneic skin. We found that CD8 depleted mice did rejectMHC class I disparate skin
grafts, but onlywhen the grafts also expressed additional alloantigens . Despite the marked depletion
of CD8+ T cells in these mice, we found that their rejection ofMHC class I disparate grafts
was mediated by CD8+ cytolytic T lymphocyte (CTL) effectors that had escaped depletion.
These CD8+ CTL effectors were unique in that : (a) their generation was dependent upon the
injected anti-CD8 mAb and upon exposure to class IMHC alloantigens expressed on the engrafted
skin, and (b) their effector function was resistant to blockade by anti-CD8 mAb . We observed
that the additional alloantigens coexpressed onMHC class I disparate grafts that triggered graft
rejection in C138-depleted mice could be MHC-linked or not and that they functioned in these
rejection responses to activate third party specific CD4+ T helper (Th) cells to provide helper
signals for the generation ofCD8+ anti-CD8 resistant CTL effector cells. Thus, mice depleted
ofCD8 + T cells by thymectomy and in vivo administration of anti-CD8 mAb harbor a unique
population of anti-CD8 resistant, CD8+ effector cells that mediate anti-MHC class I responses
in vivo and in vitro, but require help from third party specific Th cells to do so.
jection of skin allografts results from massive tissue in- R
e
.jury inflicted by immunocompetent cytolytic T cells
in response to allogeneic histocompatibility antigens expressed
by the engrafted tissue (1-3) . Studies in which isolated popu-
lations of CD8+ and CD4+ T cells were adoptively trans-
ferred into immunodeficient mice revealed that rejection of
MHC class I disparate skin grafts was mediated exclusively
by CD8+ T cells in the absence ofCD4+ T cells (4-6) . The
importance ofCD8+ T cells in rejection ofMHC class I dis-
parate skin grafts was confirmed in another experimental model
in which normal mice were depleted of CD8+ T cells by
in vivo administration of anti-CD8 mAb, and failed to
efficiently reject mutant MHC class I Kb'° skin grafts (7) .
This same experimental model was used to further investigate
the rejection ofMHC class I disparate grafts across bothH-2K
andH-2D barriers inmany different strain combinations. Sur-
prisingly, it was reported that in some strain combinations,
CD8-depleted mice could still rapidly rejectMHC class I dis-
parate grafts, raising the possibility that cells other than
CD8+ T cells might be able to effect rejection of some
MHC class I disparate grafts (7) . In considering the results
of this previous study, we noted that mice depleted of
CD8+ T cells by in vivo injection of anti-CD8 mAb
efficiently rejected MHC class I disparate skin grafts primarily
when the grafts also expressed additional histocompatibility
antigens encoded by genes to the right of H-2D . The role
that such additional antigens might have played in the rejec-
tion responses of CD8-depleted mice was not apparent .
We undertook the present study to identify the cellular
mechanisms by which mice depleted ofCD8+ T cells could
reject MHC class I disparate skin grafts. In the present study,
the experimental mice were depleted of CD8+ T cells by
adult thymectomy (ATX)t followed by in vivo anti-CD8
mAb treatment, and are referred to as CD8 - mice. Surpris-
ingly, we found that rejection ofMHC class I disparate skin
grafts by CD8- mice was mediated by a small, unique
subset ofCD8+ T cells that escaped elimination . These sur-
1 Abbreviations used in this paper . ATX, adult thymectomy ; pCTL,
precursor cytolytic T lymphocyte; kC, rabbit complement .
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rise to CTL whose effector function was resistant to blockade
by anti-CD8 mAb. The in vivo generation of such CD8+
anti-CD8 resistant CTL required engagementof MHC class
I alloantigen expressed by the skin allografts and T cell help
from third party CD4+ Th cells reactive against non-MHC
encoded histocompatibility alloantigens expressed by the graft.
Thus, this study demonstrates that rejection of MHC class
I disparate skin grafts by mice depleted of CD8+ T cells is
nonetheless mediated by CD8+ effector T cells, albeit a
unique subset of helper dependent CD8+ T cells whose
effector function is resistant to blockade by anti-CD8 mAb.
Materials and Methods
Mouse Strains.
￿
C57BL/6NCr (B6) female mice were purchased
from the Frederick Cancer Research Facility (Frederick, MD). B6.C-
H-26.1 (bml) (8) male and female mice were purchased from The
Jackson Laboratory (Bar Harbor, ME). B6.K1 (9-11) and B6Tla'
(10-12) mice were bred in our colony, from original breeding pairs
generously provided by Dr. Lorraine Flaherty, New York State
Departmentof Health (Albany, NY). The MHC, Qa-1, and Qa-2
phenotypes of thesemice are listed in Table 1. The phenotypes of
antigens encoded to the right of Qa-2 are poorly defined and are
not listed.
Adult Thymectomy (ATX) and Antibody Depletions.
￿
Mice were
thymectomized under direct visualization by sternotomy at 8-12-
wk-of-age. They were rested for 2 wk and then given three con-
secutive dailyi.p. doses of2.43 mAb (1 ml/dose) and an additional
dose 1 wk later. Depletion ofT cell subsets was monitored by im-
munofluorescence and flow cytometry.
Monoclonal Antibodies UsedIn Vitro Depletions.
￿
Anti-CD8 mAb
was used as an .ascitic fluid of the hybridoma cell line 2.43 (13),
a rat IgGzb antibody. Ascites was diluted 1:10 in PBS, filtered and
injected intraperitoneally. Anti-CD4 mAb was used as an ascitic
fluid of the hybridoma cell line GK 1.5 (14), a rat IgG2b antibody.
GK 1.5 ascites was diluted 1:4 in PBS, filtered and injected in-
traperitoneally.
Monoclonal Antibodies Used in In Vitro Depletions, Blocking and
Immunofluorescence Studies. Monoclonal anti-CD4 antibody was
either a culture supernatant of the hybridoma cell line H129.1a (15)
or RI 172/4 (16). Monoclonal anti-Lyt2.2 antibody was a culture
supernatant ofthe cell line 83-12-5 (17) or 2.43 (13). Anti-Fc receptor
mAb, 2AG2 (18) was used to block nonspecific uptake ofantibody
by FcR' cells in immunofluorescence studies. FITC-conjugated
MAR 18.5 (mouse anti-rat Ig) was purchased from Becton Dick-
inson Immunocytometry Systems (San Jose, CA).
Skin Grafting.
￿
Recipient mice were engrafted within 3 wk of
antibody depletion on the left flankwith one or two tailskin grafts
from donor animals, according to an adaptation of the method of
Billingham and Medawar (19), as previously described (20). Bandages
were removed on day 7 and the grafts scored daily until rejection
or the endpoint of the experiment (60 d). Grafts were considered
rejected when >80% of the grafted tissue was destroyed.
Flow Cytometric Analysis.
￿
Cellswere indirectly stained with anti-
CD8 mAb followed by fluoresceinated mouse anti-rat Ig (MAR
18.5) as indicated, before in vitro culturing and samples were ana-
lyzed on a modified dual laser (488 nm, 590 nm) FACS II® (Becton
Dickinson Immunocytometry Systems). Fluorescence data werecol-
lected using three-decade logarithmic amplification on viable cells
as determined by forward light scatter intensity and propidium io-
dide exclusion.
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In Vitro Cytolytic T Cell (CTL) Responses.
￿
Spleen cells (4-5 x
106) from eit er normal untreated or antibody injected mice were
cocultured with 3,300R-irradiated (1 R = 0.258 mC/kg) spleen
stimulator cells (4-5 x 106) in 2-ml cultures for 5 d as described
(21) and assayed for cytolytic activity on 5'Cr-labeled lipopolysac-
charide induced blast cells as target cells in a 4-h "Cr-release assay.
Percent specific lysis = 100 x ([experimental-spontaneous re-
lease]/[maximum-spontaneous release]).
Antibody-plus Complement TreatmentofElector Cells.
￿
Depletion
of CD4+ cells or CD8+ cells was accomplished by incubating
spleen cells at a density of 107 cells/ml with anti-CD4 mAb (1:2
dilution ofculture supernatant RL172), anti-CD8 mAb (1:2 dilu-
tion ofculture supernatant 83-12-5), or medium alone, respectively,
for 30 min on ice. Cells were then pelleted, resuspended, and in-
cubated with rabbit complement (RC') (Pel-Freeze, Brown Deer,
Wisconsin) diluted 1:10 at a density of 107 cells/ml for 30 min at
37° C. Control cultures were treated with RC' alone. Treated cells
were washed three times and reconstituted, without recounting,
to the desired concentration based on cell counts for the RC' alone
treated culture.
Antibody Blocking ofElector Cells.
￿
Blocking of CTL effectors
was accomplished by preincubating effector cells with 25% mAb
culture supernatant for 30 min at 37°C. Then,
51Cr-labeled targets
were added leaving the antibody in the cultures during the 4-h
"Cr-release assay.
Results
Skin Allograft Rejection in CD8- Mice
Construction ofCD8- Mice.
￿
To investigate the rejection
of MHC class I disparate skin grafts in mice depleted of
CD8 + T cells in vivo, we constructed "CD8 - " mice ac-
cording to the following protocol. Female mice were thymec-
tomized at 8-12-wk-of-age to prevent the emergence of new
T cells, rested for 2 wk, and then given three consecutive
daily i.p. injections of anti-CD8 mAb. An additional dose
of anti-CD8 mAb was given 1 wk later. Treated animals were
skin grafted within 3 wk of the final antibody treatment.
To assess the efficacy of CD8+ T cell depletion, T cell
populations present in treated mice were assessed by im-
munofluorescence and flow cytometry. As can be seen in Table
2, < 1% of splenocytes were CD8+, indicating that effec-
tive depletion of CD8+ T cells was achieved using this
" Strain type is inferred from the typing of B10.AQR from which this
recombinant strain was derived.
protocol.
Table 1. Phenotype of Mice Used in this Study
H-2 alleles
Strain K IA D L Qa-1 Qa-2
B6 b b b b b (+)
B6-Tla' b b b b a ( + )
B6 .K1 b b b b b ( - )
bml bml b b b b (+)
B10.YBR' b b d d a (+)Table 2 .
￿
Flow Cytometric Analysis ofSpleen Cells from Mice Treated in Vivo with anti-CD8 mAb
T cell subsets were assessed 2 wk before skin engraftment .
t T cell subsets were assessed 10 wk after skin engraftment (after rejection) .
5 Mean ± SEM .
Rejection ofH-2D andH-2K Disparate Skin Grafts by CD8-
Mice To test whether CD8 - mice responded differently to
skin grafts across anH-2K versus anH-2D disparity, individual
CD8' B6 mice were simultaneously engrafted with two
MHC class I disparate skin grafts: abml skin graft expressing
Kb- 1 allodeterminants and a B10YBR skin graft expressing
Dd and Ld allodeterminants. Unlike normal B6 mice which
reject bml skin grafts, CD8 - B6 mice did not reject bml
skin allografts but did efficiently reject B10YBR skin grafts
(Fig. 1) . To explain why CD8' mice rejected B10YBR
grafts, we considered that CD8+ T cells might have ex-
panded to significant numbers in vivo followingengraftment .
Therefore, we analyzed splenocytes from CD8- mice that
had rejectedB10YBR skin grafts. As shown in Table 2, spleen
cell populations from animals that had rejected B10YBR skin
grafts were still depleted ofCD8+ T cells. We next consid-
ered that CD8' B6 mice rejected B10YBR skin grafts be-
cause B10YBR skin grafts expressed additional histocom-
patibility disparities to the right of H-2D that would be
recognized as foreign by theB6 host. To investigate this pos-
sibility, we used B6.K1 and B6Xla' mice, which are H-2b
but differ fromB6 mice in expression ofantigens to the right
of H-2D. So, whereas burl skin grafts express only a Kbml
disparity to B6 host mice, bml skin grafts express both Kbml
and additional alloantigenic differences to the right ofH-2D
to B6.K1 andB6Tla' host mice. We therefore engrafted in-
dividual B6.K1 and B6Tla' mice with both bml and
B10.YBR skin grafts . As can be seen in Fig. 2, CD8- B6.K1
and B6Tla' mice efficiently rejected bml skin grafts whereas
CD8 - B6 mice failed to do so. In contrast, all three strains
rejected B10YBR skin grafts. Thus, these results suggested
that rejection by CD8 - mice ofMHC class I disparate skin
grafts requires the expression by the graft of additional
histocompatibility disparities and that antigens encoded by
genes to the right ofH-2D provide these additional disparities.
MHC Class I Specific CTL Ejector Cells in CD8 - Mice.
We next investigated the phenotype of the effector T cells
mediating anti-MHC class I responses in CD8- mice. As
can be seen in Fig. 3 (left), bml-specific effector cells from
untreated B6.K1 animals are CD8+, as they are eliminated
by treatment with anti-CD8mAb and C' (Fig . 3, lower left) .
Surprisingly, CTL mediating anti-bml responses in CD8-
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B6.K1 mice (Fig. 3, right) are also CD8+ , as the cytolytic
effector cells are also eliminated by treatment with anti-CD8
mAb and C' (Fig. 3, lower right), but not by anti-CD4 mAb
and C' (data not shown) . Importantly, and in marked con-
trast to the normal animal (Fig. 3, top left), bml specific CTL
in CD8- mice were not blocked by addition of anti-CD8
mAb to the effector culture (Fig . 3, top right) . Thus, these
1001
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Figure l .
￿
CD8 - B6 mice reject B10YBR skin allografts but not bml
skin allografts. On day 0, individualCD8 - B6 mice were simultaneously
engrafted with B10YBR (" ) and bml (O) tail skin grafts. The grafts
were scored daily. Survival curves reflect rejection responses ofseven animals.
Median Survival Time (MST) were 17 d for B10.YBR skin grafts and
>60 d for bml skin grafts .
Mice Treatment Skin graft CD4
% Cells staining positive for :
CD8 Thy1.2
6 None none 19 ± 1.15 12.8 ± 0.8 32.6 ± 2.0
4 ATX + anti-CD8 mAb pre" 14.2 ± 1.0 0.1 ± 0.07 16 .3 ± 0.3
10 ATX + anti-CD8 mAb post$ 15 ± 1.1 0.9 ± 0.1 19.4 ± 1 .3bmi Skin Graft
￿
B10.YBR Skin Graft
Figure 2 .
￿
Rejection of bml and B10.YBR skin allografts by H-2b con-
genic B6, B6Tlaa, and B6.K1 mice. On day 0, individual B6 (O), B6Tlaa
(p) and B6.K1 (A) mice were simultaneously engrafted with bml and
B10YBR tail skin grafts. The grafts were inspected daily. The number
ofexperimental animals in each responder group is shown in parentheses .
MST for bml grafts : B6 mice >60 days ; B6Tlaa mice=21 d; B6.Kl
mice-22 d. MST for B10YBR grafts : B6 mice=17 d ; B6Xlaa mice=11
d ; B6.K1 mice=15 d .
results demonstrate that bml specific effector cells in CD8-
B6.K1 mice are CD8+, but anti-CD8 resistant in that their
effector function is not blocked by anti-CD8 mAb .
To establish whether CD8- mice generated H-2D al-
lospecific CTL, as well as H-2K allospecific CTL, we ana-
lyzed Da and Kbm' specific CTL from CD8- B6.TLaa mice.
As shown in Fig. 4, CD8- mice generated CD8+ effector
cells specific forboth B10YBR and bml target cells as both
effector cell populations were eliminated by treatment of
effectors with anti-CD8 mAb and RC' (Fig . 4, lower right) .
However, bml andB10.YBR specificCTLeffectors were not
blocked by addition of anti-CD8 mAb to effector cultures
(Fig. 4, upper right) . Thus, even though CD8- mice are
markedly depleted of CD8+ T cells (Table 2), the effector
cells mediating anti-MHC class I responses in these mice are
a distinct subset of CD8+ CTL whose precursors are not
depleted by in vivo anti-CD8 mAb treatment and whose
effector function is not inhibited by anti-CD8 mAb.
Generation ofAnti-Kemt CTL in CD8- Mice Requires En-
graftment with Allogeneic bml Skin . We next determined if
Kbmt specific, anti-CD8 resistant precursor CTL (pCTL) had
been generated in CD8- B6.K1 mice before engraftment
with skin allografts, or if they only were generated subse-
quent to in vivo exposure to Kbm' alloantigen expressed on
bml skin grafts . To distinguishbetween these two possibili-
ties, we assessed the same individual CD8- B6.K1 mice
(#195 and #199) before and after engraftment with allogeneic
skin . Thus, individual CD8- mice underwent hemisplenec-
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Figure 3 .
￿
CD8 - B6.K1 mice that rejected bml skin grafts generate
Kbml specific CTL effector cells that are CD8* but not inhibited by anti-
CD8 mAb. Spleen cells from CD8- B6.K1 mice that had rejected bml
skin allografts (right) and spleen cells from normal unengrafted B6.K1 mice
(left) were cultured with irradiated bml stimulator cells. After 5 d in cul-
ture, effector cells were harvested and assessed for generation of Kbm'
specific CTL . The phenotype of Kbml specific CTL effector cells was as-
sessed by depletion of T cell subpopulations before their incubation with
bml target cells by treatment with anti-CD8 mAb + RC' (p), or with
RC' alone (O) (bottom) . To assess the ability of mAb to inhibit Kbm'
specific CTL effector function, unfractionated effectorcells were incubated
with bmi target cells in the presence of anti-CD4 mAb (" ), anti-CD8
mAb ("), or no mAb (" ) (top). Target cells in this and all subsequent
experiments are s'Cr-labeled LPS blasts from spleen cell precursors. Lysis
of syngeneic B6.K1 target cells was always <2% .
tomy before skin grafting and again following rejection of
bml skin allografts. Before skin grafting, splenocytes from
CD8- B6.K1 mice contained very few CD8+ T cells and
Kbmt CTL were not detected, whereas splenocytes from the
normal undepleted B6.K1 mouse generated a strong CTL
response to Kbm' allodeterminants (Fig . 5) . However, fol-
lowing rejection ofbml skin grafts, splenocytes from the same
CD8- B6.K1 mice did generate anti-Kbmt CTL despite the
persistent depletion of CD8+ T cells (Fig . 5) . Thus, failure
to detect anti-CD8 resistant Kbm' specific CTL effectors in
CD8- mice before engraftment indicates that their genera-
tion is contingent on activation of pCTL in vivo by alloan-
tigen expressed on skin grafts .
Recruitment ofAdditional Th Cells Triggers Rejection ofMHC
Class I Disparate Skin Grafts in CD8- Mice.
￿
Because rejec-
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Figure 4 .
￿
CD8- B6Tlaa mice generate CD8+ anti-CD8 resistant CTL
effectors to both H-2K and H-2D alloantigens. Spleen cells from CD8 -
B6Tla- mice that had rejected bml andB10YBR skin grafts (right) and
from normal unengrafted B6.T122 mice (left) were cultured with irradi-
ated B10YBR or bml stimulator cells. After 5 d, effector cells were har-
vested, and tested for their ability to lyse bml and B10.YBR target cells.
CTL effectors were phenotyped by depletion ofeffector cells before incu-
bation with bml and B10.YBR target cells with anti-CD8mAb + RC'
(p) or with RC' alone (O) (bottom) . mAb inhibition of CTL effector func-
tion was tested by culture of unfractionated effector cells with bml or
B10.YBR target cells in the presence of anti-CD8 mAb ("), anti-CD4
mAb (A), or no mAb (" ) (top) . Lysis of syngeneic B6.Tla- target cells
was always <2% .
tion ofMHC class I disparate skin allografts by CD8 - mice
appeared to be contingent on the expression of additional
histocompatibility disparities to the right ofH-2D, we wished
to determine why expression ofsuch additional antigens was
necessary. It was possible that these additional antigens were
the true target specificities of effector cells or, alternatively,
that they were helper specificities that were necessary for the
in vivo activation of distinct populations of Th cells.
Because alloantigens encoded by genes to the right ofH-2D
are relatively poorly defined, we wished to determine if a
well-defined non-MHC encoded alloantigen could substitute
for them . For example, H-Y alloantigen is a male specific
minor-histocompatibility antigen which is not encoded by
H-2 but which does activate CD4+ Th cells in B6 female
mice (6, 22) . Thus, we asked whether CD8 - mice could re-
ject an isolatedMHC class I disparate graft that did not ex-
press additional differences to the right ofH-2D, but instead
expressed the male antigenHY CD8" female B6 mice were
engrafted simultaneously with two bml skin grafts: an "in-
ducer" bml male graft that expressed both Kbm1 and H-Y
alloantigens, and an "indicator" bml female graft which ex-
pressed only Kbm1 alloantigen . As shown in Table 3, CD8 -
B6 mice engrafted with a bml female "inducer" graft did
not reject their bml female "indicator" grafts (group 1) . In
contrast, CD8- B6 mice engrafted with a bml male "in-
ducer" graft did efficiently reject their bml female indicator
grafts (group 2), indicating that CD8 - B6 mice can reject
skin allografts expressing an isolatedMHC class I Kbro1 dis-
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Figure 5 .
￿
Generation of anti-Kbml specific CTL effector cells in CDS -
mice requires in vivo exposure to bml skin grafts . Spleen cells from two
individual CD8 - B6.K1 mice (#195 and #199) were obtained by hemi-
splenectomy and tested before engraftment (top right) and following rejec-
tion of bml skin grafts (bottom right) for the presence of Kbml specific CTL
effector cells and for the percentage of CD8* T cells. Responder cells were
incubated with irradiated bml stimulator cells for 5 d and then tested for
lysis ofbml target cells. Percentage of CD8 + T cells was assessed by im-
munofluorescence and flow cytometry. Spleen cells from normal unen-
grafted B6.K1 animals served as positive controls (left) . Lysis of syngeneic
B6.K1 target cells was <2% .
parity without any additional differences, so long as the mice
were engrafted with an inducer graft capable of additionally
activating third party Th cells.
We then characterized the anti-WO- 1 effector cells gener-
ated in CD8- B6 female mice in response to bml male skin
grafts to see if they resembled the anti-Kbm 1 effector cells
generated in CD8 - B6.K1 and B6Tlaa mice (Fig . 3 and 4) .
As can be seen in Fig. 6, anti-Kbm 1 CTL were generated
from the spleens of CD8 - B6 female mice engrafted with
bml male inducer grafts, and these CTL were indistinguish-
able from those generated in CD8 - B6.K1 and B6Xla2 mice
(to which the bml skin allograft expressed additional allo-
antigens encoded by genes to the right of H-2D), in that
the anti-bml CTL were CD8+ but anti-CD8 resistant (com-
pare Figs . 3 and 4 and Fig . 6, right) . Thus, the generation
of anti-bml rejection responses mediated by CD8+ anti-
CD8 resistant CTL in CD8 - B6 mice required expression
by the bml skin graft ofadditional alloantigens, but the pre-
cise identity of the additional alloantigens expressed by the
skin allograft was unimportant in that they could be encoded
by genes linked to the MHC or not .
To determine ifthe required expression ofH-Y alloantigen
on inducer bml male grafts triggered rejection ofbml fe-
male indicator grafts by CD8 - B6 female mice because
generation ofanti-HY CTL effector cells was required, we
assessed the ability of splenocytes from rejector CD8 - B6
810 . YBR bmt B10 .YBR bml
o-o ---0
% CDB'<0.1 % CD8'-0 .3
% CD8'-0 .9 % CD8'-0.7" Thymectomized B6 female mice were treated with four doses of the indicated mAb(s) and engrafted with skin from the indicated donor mice.
t MST-Median Survival Time .
S F = female .
IIM = male .
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Figure 6.
￿
CD8 - B6 female mice generate CD8' anti-CD8 resistant
CTL specific for Kbm1 following rejection of burl male skin grafts . Re-
sponder cells from the spleen of an individualCD8 - B6 mouse that had
rejected abml skin graft (right) or from a normal unengrafted B6 mouse
(left) were cultured with irradiated bml stimulator cells for 5 d . Effector
cells were phenotyped by treatment with anti-CD8mAb + RC' (p) or
RC' alone (O) prior to incubation with bml target cells (bottom) . mAb
inhibition ofCTL effector function was assessed by incubation of effector
cells with bml target cells in the presence of anti-CD8 mAb (") or ab-
sence of anti-CD8 mAb (") (top) . Lysis of syngeneic B6 female target
cells was <2%.
1468
￿
Skin Allograft Rejection in CD8 - Mice
mice to generate anti-HY as well as anti-Kbmt CTL . In con-
trast to their ability to generate anti-Kbmt CTL (Fig. 7,
right), splenocytes from CD8- B6 mice were unable to
generate anti-HY CTL despite the fact that the mice had
been engrafted withbml male inducer grafts expressing both
Kbm1 and HY alloantigens (Fig . 7, left) . Thus, this result
demonstrates that CD8- mice are limited in the alloantigens
against which they are able to generate CTL . More impor-
tantly, this result indicates that the requirement forH-Y al-
loantigen expression by the bml inducer graft is not as an
additional CTL target specificity.
To document the possibility that expression of the H-Y
alloantigen on bml male inducer grafts functioned to acti-
vate CD4+ Th cells in vivo, we treated mice in vivo with
anti-CD4 mAb . It can be seen that in vivo anti-CD4 mAb
treatment of mice that were thymectomized but not T cell
depleted, did not itself interfere with the in vivo generation
ofanti-bml effector cells mediating bml-specific rejection re-
sponses (Table 3, group 4) . However, in vivo anti-CD4mAb
treatment ofCD8- mice did block the generation of bm1-
specific rejection responses in CD8 - B6 female mice en-
grafted with B6 male inducer grafts (Table 3, group 3) .
Taken together these data indicate that, in CD8 - B6 fe-
Table 3. Rejection of bml Skin Grafts by Mice Depleted of
Inducer skin
T Cell Subsets
graft
in Vivo
Indicator skin graft
ATX B6F host` Antigen MST# Antigen MST
Group treatment Strain disparity # Rejected (d) Strain disparity # Rejected (d)
1 anti-CD8 bml FS Kbm' 0/8 >60 bml F Kbml 0/8 >60
2 anti-CD8 bml MN Kb-' +H-Y 8/8 19 bml F Kbmt 8/8 22.5
3 anti-CD8 bmlM Kbm' +H-Y 1/5 >50 bml F Kbml 1/5 >50
+ anti-CD4
4 anti-CD4 bmlM Kbm'+H-Y 5/5 8 bml F Kbml 5/5 8
5 PBS bml F Kbm' 4/4 22 bml F Kbml 4/4 23
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Figure 7 . CD8- B6 female mice generate anti-Kb'nt, but not anti-
HY CTL following rejection ofbml male skin grafts. Responder cells
from a CD8 - B6 mouse that had rejected a bml male skin graft or from
control ATX mice that had rejected B6 male skin grafts were cultured
with bml male stimulator cells. After 5 d, effector cells were harvested
and tested for their ability to lyse both B6 male targets (left) and bml
female target cells (right). (0)CD8 - responder (O) controlATX mouse.
Lysis of syngeneic B6 female target cells was <2% .
male mice, theHY alloantigen expressed by the bml male
inducer graft functioned to activate CD4+ Th cells which,
in turn, were required for the generation of CD8+ anti-
CD8 resistant CTL specific for Kbmt determinants expressed
by the bml inducer and indicator grafts.
Discussion
The elimination ofT cell subsets in vivo by treatment of
animals with specific mAbs is a powerful tool for dissecting
cellular mechanisms involved in immunologic responses . How-
ever, the present study demonstrates that despite marked deple-
tion ofCD8 + T cells in mice treated in vivo with anti-CD8
mAb, a unique subpopulation of CD8 + T cells remains
which mediates rejection ofMHC class I disparate skin grafts
in vivo and generates allospecific CTL responses in vitro.
The unique CD8+ T cell population that is not depleted
by anti-CD8 mAb in vivo and mediates anti-MHC class I
responses is distinguished from CD8+ T effector cells nor-
mally mediating such responses in that (a) their cytolytic
effector function is not inhibited by anti-CD8 mAb in vitro
and so they are anti-CD8 "resistant" and (b) they are exqui-
sitely dependent on an exogenous source ofT cell help for
activation . The generation of CD8 + anti-CD8 resistant
Kb-1 specific CTL effector cells in vivo is contingent on
three factors : exposure ofpCTL to anti-CD8mAb, exposure
of pCTL to alloantigen, and provision of T cell help from
Th cells specific for third party alloantigens expressed by the
graft . Thus, in these respects the cells appear identical to in
vitro generated CD8 + anti-CD8 resistant CTL which have
been previously described (23-24) .
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The mechanism by which anti-CD8 mAb induces anti-
CD8 resistant CD8+ T cells in vivo is likely to be similar
to that by which it induces such cells in vitro. However, anti-
CD8 resistant CTL were generated in vitro only when the
CD8 determinants on CD8 + pCTL were multivalently
crosslinkedbymAb, a process which induced thedown modu-
lation of cell surface CD8 on these cells (23-24) . Indeed, in
the present study, bivalently bound IgG anti-CD8mAb would
be multivalently crosslinked in vivo by further binding to
Fc receptors present in vivo on FcR+ cells . Importantly, the
reduced surface expression of CD8 induced by multivalent
anti-CD8 crosslinking might explain why anti-CD8 resis-
tant CD8 + T cells escape depletion in vivo.
A further requirement for generation of anti-CD8 resis-
tant CD8+ CTL effector cells is exposure of precursor cells
to alloantigen, indicating that generation of these cells is an
antigen specific event requiring engagement ofTCR . Interest-
ingly, however, anti-CD8 resistant H-Y specific CTL were
not generated despite administration of anti-CD8 mAb and
engraftment with anH-Y expressing allograft, indicating that
the repertoire of anti-CD8 resistant CD8+ effector cells is
not as extensive as that of normal CD8+ T cells. It is con-
ceivable that high levels of antigen-induced TCR crosslinking
are required to trigger anti-CD8 resistant effector cells, so
that only antigens expressed in high quantities on graft cells
are able to successfully trigger such cells.
The final requirement for in vivo generation of anti-CD8
resistant CD8+ effector cells is the recruitment and activa-
tion of additional CD4+ Th cells. In most cases, such CD4+
Th cells are not triggered by isolatedMHC class I disparities
expressed by skin grafts, but rather are triggered by the third
party alloantigens expressed by the graft . In the present study,
we have demonstrated that such third party alloantigens need
not be linked to the MHC, and that any antigen capable of
activating CD4+ Th cells should be capable of providing the
necessary signals for anti-CD8 resistant CD8+ effector cells.
We think that failure of anti-CD8 mAb treatment to block
rejection of someMHC class I disparate skin grafts results
from their expression of additional histocompatibility alloan-
tigens which trigger CD4+ Th cells necessary for the acti-
vation of CD8+ anti-CD8 resistant effector cells in these
mice. Indeed, production of alloantibody by CD8 - mice en-
grafted withMHC class I disparate skin (7) is presumptive evi-
dence that the grafts did activate CD4+ Th cells, as such
cells are essential for generation ofH-2 specific humoral re-
sponses (25) . The requirement for additional antigens to ac-
tivate CD4+ Th cells in CD8- mice dramatizes the failure
ofMHC class I H-2K alloantigen expressed on skin grafts
to activate CD4+ Th cells in vivo (4) . In contrast, MHC
class I H-2K alloantigen on spleen APCs do activate CD4+
Th cells that recognize peptides ofMHC class I alloantigen
presented byAPC Ia determinants (26) . We think that failure
ofMHC class I H-2K alloantigen expressed on skin grafts
to activate such CD4+ Th cells (4) results from defects in
the ability of Langerhans cells, the predominant APC popu-
lation in skin, to present class IMHC alloantigens in associ-
ation with Ia determinants to allospecific CD4+ Th cells.
Indeed, the markedly diminished expression ofH-2K classIMHC antigen on Langerhans cells (27) is consistent with
a cellular defect in the expression and perhaps processing
(28-30) ofMHC class I H-2K antigens by these cells.
In summary, the present study demonstrates that mice
depleted ofCD8+ T cells by in vivo administration of anti-
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